证券代码：003020 证券简称：立方制药 公告编号：2025-051 合肥立方制药股份有限公司 第五届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 合肥立方制药股份有限公司（以下简称"公司"）第五届董事会第二十二次 会议于 2025 年 8 月 8 日以电子邮件、电话、短信等方式通知公司全体董事。会 议于 2025 年 8 月 12 日在公司会议室以现场结合通讯表决方式召开，会议应出席 董事 7 人，实际出席董事 7 人，其中以通讯方式出席会议董事 1 人，独立董事李 进华先生以通讯方式出席会议并表决。公司部分监事、高级管理人员列席了会议。 会议由公司董事长季俊虬先生主持。 本次董事会会议的召集、召开程序符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》《董事会议事规则》的规定。 二、董事会会议审议情况 与会董事经过认真审议并投票表决，审议通过了如下议案： 1、《关于修订〈公司章程〉并办理工商登记的议案》 （1）同意将公司董事会成员人数由 7 名调整为 8 名，其中非独立董事 5 名 （含职工 ...

Company Performance - As of August 8, 2025, Lifan Pharmaceutical (stock code 003020) closed at 27.1 yuan, down 0.88%, with a turnover rate of 5.63% and a trading volume of 77,600 lots, amounting to 211 million yuan [1] - The latest quarterly report shows total revenue of 360 million yuan, a year-on-year increase of 7.98%, and a net profit attributable to shareholders of 38.25 million yuan, up 25.94% year-on-year [1] - The company's non-recurring net profit was 31.60 million yuan, reflecting an 11.28% year-on-year growth [1] - Financial ratios include a current ratio of 2.142, a quick ratio of 1.723, and a debt-to-asset ratio of 24.82% [1] Capital Flow - On the reporting day, the net outflow of main funds was 32.19 million yuan, accounting for 15.24% of the total transaction amount [1] - Large orders saw a net outflow of 27.09 million yuan, representing 12.82% of the transaction amount, while small orders had a net inflow of 40.26 million yuan, making up 19.06% of the transaction amount [1] Company Background - Hefei Lifan Pharmaceutical Co., Ltd. was established in 2002 and is primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 1.9018 billion yuan and a paid-in capital of 660 million yuan [1] - The company has made investments in 11 enterprises and has participated in 5,000 bidding projects [2]

雅本化学：与恒瑞医药签署供应战略协议 8月1日晚，雅本化学（300261）发布公告称，公司与江苏恒瑞医药股份有限公司签署《供应战略协 议》，建立面向未来的战略合作伙伴关系。双方将共同推动特定医药中间体及原料药（API）产品的技 术创新与质量升级，强化医药产业链关键环节的协同竞争力。协议有效期为10年，自2025年8月1日起生 效。 资料显示，雅本化学成立于2006年1月，主营业务是创新农药中间体、医药中间体的研发、生产和销 售。 所属行业：基础化工–农化制品–农药 巍华新材：拟收购禾裕泰控股权 8月1日晚，巍华新材（603310）发布公告称，公司与浙江欣禾生物股份有限公司签署股权收购意向协 议，拟以现金方式收购江苏禾裕泰化学有限公司的控股权。此次收购旨在延伸公司产品链，发挥协同效 应，提升公司在行业内的综合竞争力。目前，收购事项尚处于筹划阶段。 资料显示，巍华新材成立于2013年10月，主营业务是研发、生产氯甲苯类和三氟甲基苯类系列产品。 所属行业：基础化工–化学制品–氟化工 富吉瑞：获得200.74万元政府补助 8月1日晚，富吉瑞（688272）发布公告称，公司近日收到政府补助200.74万元。该补助为与收 ...

Key Points - Tibet Tourism may apply for suspension of trading if significant abnormalities occur in stock transactions [1] - Southern Road Machinery's stock price has deviated from its fundamental situation [1] - Industrial Fulian's major customers and products have not undergone significant changes [1] - Yingweike has established a relatively complete liquid cooling technology and product solution capability [1] - Victory Energy's operational situation remains normal with no significant changes in the internal and external business environment [1] - Qizheng Tibetan Medicine's operational situation is normal with no significant changes in the internal and external business environment [1] - Dongxin Co. states that its investment in Shanghai Lishuan's chip products is not applicable for large model computing clusters [1] - Guosheng Co. has obtained project filing related to PEEK from its wholly-owned subsidiary [1] - Action Education's actual controller proposed a mid-term dividend of 10 yuan per 10 shares [1] Mergers and Acquisitions - Darui Electronics plans to acquire 80% of Weiste's equity through capital increase and share acquisition [1] - Dashengda intends to acquire 30% equity of Thailand's Far East [1] Financing - Aoshikang plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [1] - Sixuan New Materials intends to raise no more than 466 million yuan through a private placement [1] - Changhua Chemical plans to raise no more than 230 million yuan for a carbon dioxide polyether project [1] Share Buybacks and Reductions - Fuanna plans to repurchase shares worth between 55.85 million and 104 million yuan [1] - Jiangnan Yifan's board member intends to increase his stake in the company [1] - Jieya Co. and its concerted parties plan to reduce their holdings by no more than 4.95% [1] - Other companies including Tongda Co., Haohan Deep, and Wanhu Chemical also plan to reduce their holdings [1] Operational Data - Sinopec expects a net profit decline of 39.5% to 43.7% year-on-year for the first half of the year [1] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half, up 16.05% year-on-year [1] - Daodaquan's net profit increased by 563.15% year-on-year, proposing a dividend of 1.76 yuan per 10 shares [1] - Zhengdan Co. reported a net profit increase of 120.35% year-on-year, proposing a dividend of 3 yuan per 10 shares [1] - Other companies reported varying profit changes, including losses and significant increases [1] Contracts and Major Investments - Sanhui Electric signed a framework contract for robot equipment sales [1] - Zhejiang University Network New's subsidiary won a smart engineering project worth 94.2712 million yuan [1] - New Aluminum Times plans to invest no less than 500 million yuan in a project for lightweight, high-strength auto parts [1] - Zhishang Technology will use part of its raised funds for a smart manufacturing production base in Vietnam [1]

Group 1 - The company, Hefei Lifan Pharmaceutical Co., Ltd., has received the drug registration certificate for Mesalazine enteric-coated tablets from the National Medical Products Administration [1] - Mesalazine is a non-steroidal anti-inflammatory drug that significantly inhibits inflammation in the intestinal mucosa, suitable for treating acute episodes of ulcerative colitis and maintaining remission, as well as treating acute episodes of Crohn's disease [1] - The approval of Mesalazine enteric-coated tablets will enhance the company's product pipeline and market competitiveness, with four other domestic companies holding the same specification drug approval and three others holding different specifications [1]

证券日报网讯 7月31日晚间，立方制药发布公告称，近日，公司收到国家药品监督管理局核准签发的美 沙拉秦肠溶片《药品注册证书》。 （文章来源：证券日报） ...

立方制药（003020）(003020.SZ)公告，公司收到国家药品监督管理局核准签发的美沙拉秦肠溶片《药 品注册证书》。美沙拉秦是一种非甾体抗炎药，可以抑制引起炎症的前列腺素的合成和炎性介质白三烯 的形成，从而对肠黏膜的炎症起显著抑制作用。美沙拉秦肠溶片口服后在肠道释放美沙拉秦，适用于溃 疡性结肠炎急性发作期的治疗和防止复发的维持治疗，以及克罗恩病急性发作期的治疗，原研为德国福 克制药股份有限公司。 ...

智通财经APP讯，立方制药(003020.SZ)公告，公司收到国家药品监督管理局核准签发的美沙拉秦肠溶片 《药品注册证书》。美沙拉秦是一种非甾体抗炎药，可以抑制引起炎症的前列腺素的合成和炎性介质白 三烯的形成，从而对肠黏膜的炎症起显著抑制作用。美沙拉秦肠溶片口服后在肠道释放美沙拉秦，适用 于溃疡性结肠炎急性发作期的治疗和防止复发的维持治疗，以及克罗恩病急性发作期的治疗，原研为德 国福克制药股份有限公司。 ...

证券代码：003020 证券简称：立方制药 公告编号：2025-050 合肥立方制药股份有限公司 关于取得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、药品注册批准情况 | 药品名称： | 美沙拉秦肠溶片 | 申请事项： | 药品注册(境内生产) | | --- | --- | --- | --- | | 剂型： | 片剂 | 注册分类： | 化学药品4类 | | 规格： | 0.5g | 药品有效期： | 18个月 | | 药品批准文号： | 国药准字H20254987 | 药品批准文号 有效期： | 至2030年07月28日 | | 上市许可持有人： | | 合肥立方制药股份有限公司 | | | 生产企业： | | 合肥立方制药股份有限公司 | | 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合 药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签 及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可 生产销售。 二、药品其他相关情况 美沙拉秦是一种非甾体抗炎药，可以抑制 ...

每经AI快讯，7月31日，立方制药(003020.SZ)公告称，公司近日收到国家药品监督管理局核准签发的美 沙拉秦肠溶片《药品注册证书》。该药品适用于溃疡性结肠炎急性发作期的治疗和防止复发的维持治 疗，以及克罗恩病急性发作期的治疗。截至公告日，除进口产品及公司外，国内有4家企业持有该产品 同规格药品批文，另有3家持有其他规格药品批文。该药品注册证书的取得将进一步丰富公司产品管 线，提升市场竞争力。 ...